Topics
-
Selected for Inclusion in the FTSE4 Good Index for 12 Consecutive Years
-
World Anti-Doping Agency Coordinates Global Implementation of Sysmex Analyzers at All Blood Laboratories
-
The OncoGuide™ NCC Oncopanel System Receives Insurance Coverage for Use in Cancer Genome Profiling
-
Business Results Announcement for the Fiscal Year Ended March 31, 2019
-
Sysmex Opens Technopark East Site, a Bio-Diagnostic Reagent Base
-
Contributing to the Early Detection and Treatment of Malaria through Standardized and More Efficient Malaria Testing
Press Releases
- Sysmex Receives the 44th Inoue Harushige Prize
- Our Views and Policy regarding Investment Unit Reduction (PDF：81KB)
-
World Anti-Doping Agency Coordinates Global Implementation of Sysmex Analyzers at All Blood Laboratories
-Contributing to Clean and Fair Sports Management by Enhancing the Quality of Doping Tests- - The OncoGuide™ NCC Oncopanel System Receives Insurance Coverage for Use in Cancer Genome Profiling
- Sysmex and Osaka University Sign Comprehensive Collaboration Agreement to Foster Innovation in the Healthcare Field
